Biotech Paralegal — Governance
Enregistrez cette offre et organisez votre recherche
Créez un compte gratuit pour enregistrer des offres d'emploi, créer des alertes et revenir à cette liste depuis votre tableau de bord.
En continuant, vous acceptez nos Conditions d’utilisation & Politique de confidentialité.
argenx is seeking an experienced Paralegal to join the Legal team in Ghent, Belgium. You will support corporate governance, litigation, insurance, and business development for a fast-growing global biotech company.
Hybrid role-based in Ghent with three on-site days per week and potential international travel. Minimum 5 years of paralegal experience and a law background are required to contribute to governance, investigations, and cross-border initiatives.
-
Paralegal
Il y a 2 jours
Oost-Vlaanderen, Oost-Vlaanderen, Belgique argenx US Temps plein 52 000 € - 75 000 € ContratJoin us as we transform immunology and deliver medicines that help autoimmune patients get their lives back. argenx is preparing for multi-dimensional expansion to reach more patients through a rich pipeline of differentiated assets, led by VYVGART, our first-in-class neonatal Fc receptor blocker approved for the treatment of gMG, and with the potential to...
-
Paralegal
Il y a 4 jours
Oost-Vlaanderen, Oost-Vlaanderen, Belgique argenx SE Temps plein 60 000 € - 83 000 € ContratJoin us as we transform immunology and deliver medicines that help autoimmune patients get their lives back. argenx is preparing for multi-dimensional expansion to reach more patients through a rich pipeline of differentiated assets, led by VYVGART, our first-in-class neonatal Fc receptor blocker approved for the treatment of gMG, and with the potential to...
-
Paralegal
Il y a 4 jours
Oost-Vlaanderen, Oost-Vlaanderen, Belgique Argenx Temps plein 60 000 € - 83 000 € ContratJoin us as we transform immunology and deliver medicines that help autoimmune patients get their lives back. argenx is preparing for multi-dimensional expansion to reach more patients through a rich pipeline of differentiated assets, led by VYVGART, our first-in-class neonatal Fc receptor blocker approved for the treatment of gMG, and with the potential to...